ArticleOncoimmunology
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
Tatiana Pazina et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
55 papers cite it
pooled ittrialcites it